

# Special Issue

## Extracellular Vesicles and Nanoparticles: Mechanisms of Cellular Communication, Disease Regulation, and Biomarker Discovery

### Message from the Guest Editors

Extracellular vesicles (EVs) are increasingly identified as important players in the progression of disease by enhancing the underlying mechanisms of infection. Similarly, EVs may serve as transporters of biological "messages" allowing for the evasion of the immune system and targeting of specific cells. The overall goal of this Special Issue is to bring together expertise from the fields of infectious diseases, cell-to-cell communication, immunology, CNS, diagnostics, biomarker discovery, and nanoparticle technology to elucidate the role of EVs in the interphase between the immune system, central nervous system (CNS), and disease progression. Based on your expertise, we invite you to contribute with an original report, original observation or review, to highlight (i) mechanisms of EV biogenesis, (ii) immune pathways affected by EVs, (iii) mechanisms of EV invasion into the CNS, (iv) nanoparticle synthesis or use in diagnostics of disease, and (v) recent advances in EV-based therapeutics.

---

### Guest Editors

Dr. Daniel O. Pinto

Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA

Dr. Elke S. Bergmann-Leitner

Department of Primary Appointment, School of Medicine, Silver Spring, MD 20910, USA

---

### Deadline for manuscript submissions

closed (30 November 2022)



# Vaccines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.4**

**CiteScore 9.9**

**Indexed in PubMed**



[mdpi.com/si/77836](http://mdpi.com/si/77836)

*Vaccines*

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/](http://mdpi.com/journal/vaccines)

[vaccines](http://mdpi.com/journal/vaccines)





# Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](http://mdpi.com/journal/vaccines)

## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

